A Roadmap to Accelerate the Evidence-Based Integration of Bispecific Antibody Therapies Into DLBCL/FL Care Plans

Join us for a live webinar where leading experts in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as well as bispecific antibody therapies will discuss solutions for overcoming persistent gaps in integrating bispecific antibodies into DLBCL and FL treatment plans. Leveraging key data and insights stemming from provider surveys and recent protocol integration sessions, expert faculty will present the latest evidence and guideline recommendations for bispecific antibodies for DLBCL/FL treatment. Additionally, utilizing a bispecific antibody integration protocol developed specifically for this program, faculty will walk attendees through this roadmap, providing best practices for prescribing, administering, and managing bispecific antibodies in your setting. Don't miss this opportunity to enhance your knowledge, ask top-of-mind questions, and harness new approaches to optimize DLBCL/FL care with bispecific antibodies.